Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives

Keyphrases

• A1 Receptor 100%
• Academic Center 10%
• Clinical Experience 20%
• Endocrine Society 10%
• Gastrointestinal Side Effects 10%
• Glucagon-like 100%
• Liraglutide 20%
• Local Elevation 10%
• Local Reaction 10%
• Obesity 20%
• Pancreatic Enzymes 10%
• Patient Tolerance 10%
• Patients with Diabetes 100%
• Patients with Obesity 100%
• Pediatric Endocrine 10%
• Pediatric Obesity 10%
• Pediatric Patients 100%
• Professional Societies 10%
• Proper Use 10%
• Provider Perspectives 100%
• Receptor Agonist 100%
• Treatment Duration 10%
• Type 2 Diabetes Mellitus (T2DM) 20%

Medicine and Dentistry

• Gastrointestinal Distress 10%
• Glucagon-Like Peptide-1 Agonist 100%
• Liraglutide 20%
• Maturity Onset Diabetes of the Young 20%
• Pancreas Enzyme 10%
• Patient with Diabetes 100%
• Patient with Obesity 100%
• Pediatric Endocrinology 20%
• Pediatric Obesity 10%
• Pediatrics 10%
• Pediatrics Patient 100%
• Side Effect 10%
• Treatment Duration 10%